Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D54WUR
|
|||
| Drug Name |
Tegavivint
|
|||
| Synonyms |
Tegatrabetan; 1227637-23-1; BC2059; Tegavivint; Tegavivint [INN]; BC-2059; 18AP231HUP; CHEMBL3601411; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP; SCHEMBL14947676; BDBM50108103; NSC785527; AKOS032946684; NSC-785527; BS-14778; HY-109103; CS-0039507; D71173; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Desmoid tumour [ICD-11: 2F7C] | Phase 1 | [1] | |
| Company |
Iterion Therapeutics Houston, TX
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H36N4O6S2
|
|||
| Canonical SMILES |
CC1CC(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=C4C=CC(=CC4=C3N=O)S(=O)(=O)N5CC(CC(C5)C)C)NO)C
|
|||
| InChI |
InChI=1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,29,33H,9-10,13-16H2,1-4H3/t17-,18+,19-,20+
|
|||
| InChIKey |
OMWCXCBGEFHCTN-FGYAAKKASA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03459469) Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor. U.S.National Institutes of Health. | |||
| REF 2 | Tegavivint and the beta-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.